Efficacy and safety of biologic therapies in immune checkpoint inhibitor-induced bullous pemphigoid - PubMed
3 hours ago
- #biologic therapies
- #immune checkpoint inhibitors
- #bullous pemphigoid
- Biologic therapies like dupilumab, omalizumab, and rituximab are being studied for immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP).
- Dupilumab shows promise in treating ICI-BP, with studies indicating its efficacy and impact on cancer outcomes.
- ICI-BP is characterized by interleukin-4 and interleukin-13 expression, which may respond to targeted biologic treatments.
- Research includes retrospective analyses and case series to evaluate the frequency, clinical features, and treatment impacts of ICI-BP.
- The safety and efficacy of these biologics are critical for managing ICI-BP without compromising cancer therapy.